The gene synthesis market is the commercial market for writing custom DNA, and it sits at the center of Adam O’Dell’s “Imperium” pitch for 2027. The whole thesis rests on a single trend: DNA is getting faster and cheaper to write, and at some point that cost curve tips the technology from a specialty lab tool into a mainstream industrial input. O’Dell’s job is to convince you that tipping point is happening now, and his framing is worth taking apart carefully.
The Driver: Faster, Cheaper DNA
The core driver is a cost and speed curve that looks a lot like the one semiconductors rode for decades. The presentation quotes Twist Bioscience’s (TWST) claim that its NanoWell technology “processes DNA at 10,000 times the speed of the previous technology.” We could not independently verify that 10,000-times figure, which reads more like a marketing number than a measured statistic. What we can say with confidence is the direction: synthesis keeps getting faster and cheaper, and that matters for every industry that depends on biological inputs.
The Scale Claim
O’Dell reaches for a big number to size the opportunity. He cites McKinsey in arguing that DNA technology will “disrupt 60% of the physical inputs in the global economy,” remaking industries worth $65 trillion. That is an upper-bound, directional framing rather than a specific market forecast. The honest way to describe the gene synthesis market itself is directionally: it is growing, and it is still small relative to the industries it claims to disrupt, with no clean, citable dollar figure to pin down its exact size today.
The Key Players
On the write side, Twist Bioscience (TWST) leads with silicon-chip synthesis, and its business is genuinely steady: 15 consecutive quarters of roughly 20% revenue growth, a market cap near $7.6 billion, and near break-even adjusted cash flow. On the software side, Ginkgo Bioworks (DNA) has pivoted to autonomous lab equipment for AI and pharma customers, with a first sale to Novo Nordisk and new wins with ARPA-H and the NSF. Around them sit the incumbents: Illumina, Thermo Fisher, and Danaher compete at the equipment layer. For a closer look at the write-layer leader, see our Twist Bioscience stock piece.
Who Is Funding It
The money flowing in is real. DARPA, ARPA-H, and the NSF have put public money into DNA synthesis and DNA-driven discovery, and Amazon, Eli Lilly, and Anthropic have all spent on the technology. Amazon’s DNA program is a concrete signal: it selected Twist as its silicon layer and Ginkgo as its software layer, a modest but verifiable validation that serious buyers take the two companies seriously. You can read more about how the technology actually works in our DNA synthesis explainer.
Why It Matters Now
O’Dell’s credibility is part of why the pitch deserves a fair hearing. He began teasing Palantir in the spring of 2024 in the $20s, and it went on to be the best-performing stock in the S&P 500 for the year. That is a dated, checkable win. The Imperium thesis is a bigger, slower bet, and the names under it have changed over time, but the underlying market, the business of writing DNA, is real and expanding. For the full list of companies in the space, see our gene synthesis companies explainer.
The Timing Argument
The presentation pushes a specific urgency: a four-month window in which a “DNA index” returned more than six times the semiconductor index. That is a real, checkable window, but it is far too short to say anything about a decade-long revolution. The honest read is that the trend is real and the four-month window is a marketing flourish.
The “Next Nvidia” Framing
O’Dell also frames the opportunity in computing terms, calling the lead company the next IBM, Intel, and Nvidia in sequence, with a real path to becoming the biggest company in the world while sitting “over 600 times smaller than Nvidia right now.” The implication is a 600-times runway. The honest read is different: a life-sciences tools business is not a chip monopoly, and being smaller than Nvidia is not, by itself, the opportunity.
The Presenter’s Method
O’Dell is the chief investment strategist at Money & Markets, the publishing house behind Green Zone Fortunes, and he also runs Cycle 9 Alert and 10X Profits. His signature tool is the Green Zone Power Ratings, a quantitative system that scores stocks on momentum, value, and volatility and sorts them into a green zone of buys and a red zone of sells. That discipline gives his recommendations a consistency many newsletter pitches lack.
The Offer
The pitch is “Imperium: The No. 1 Investment for 2027,” $297 a year with a 30-day refund. The teased names, Twist around $112, Ginkgo around $8.32, and Absci around $7.58, sit inside three special reports that come with the subscription. O’Dell’s best recent call is well documented: he began teasing Palantir in the spring of 2024 in the $20s, and it became the best-performing stock in the S&P 500 that year.
The Honest Size of It
We will not pin a specific dollar figure on the gene synthesis market here, because a clean, citable number is not available. The honest way to describe it is that the market is growing, that the cost of writing DNA keeps falling, and that the biggest uncertainty is timing, not direction. A technology can be real and still take longer to arrive than a four-month chart suggests.
Ready to see the research? Click here to access Adam O’Dell’s report.
NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.